FDA Warns About Safety of Custom-Made Ozempic:
wsj.com/articles/fda-warns-about-safety-of-custom-made-ozempic-32cb1357
Story Details
| Last Updated | Jun 01 23 |
| Total Articles | 1 |
More articles on this subject
Previous
Gilead Beats Earnings Expectations After Rocky Quarter
barrons.com/articles/gilead-beats-earnings-expectations-after-rocky-quarter-e7a55ae4
Paid articlePaid
US Senate committee investigates pricing of Novo's Ozempic and Wegovy: A U.S. Senate committee said on Wednesday it had launched an investigation into the prices ...
reuters.com/business/healthcare-pharmaceuticals/us-senate-committee-investigates-pricing-novos-ozempic-wegovy-2024-04-24/
Biogen Stock Rises After Earnings and on Jump in Alzheimer’s Drug Sales: Biogen reported first-quarter adjusted earnings of $3.67 a share on revenue of $2 ...
barrons.com/articles/biogen-earnings-stock-price-fda73be6
Paid articlePaid
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy: Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss ...
nytimes.com/2024/04/20/business/ozempic-novo-nordisk-wegovy.html
German watchdog approves Novo's acquisition of Cardior Pharmaceuticals: The German cartel office has approved a deal by Denmark's Novo Nordisk to purchase ...
reuters.com/business/healthcare-pharmaceuticals/german-watchdog-approves-novos-acquisition-cardior-pharmaceuticals-2024-04-18/
Plaintiffs' lawyers chosen to lead Ozempic litigation: A federal judge has appointed eight plaintiffs' lawyers to leadership roles in federal mass tort ...
reuters.com/legal/litigation/plaintiffs-lawyers-chosen-lead-ozempic-litigation-2024-04-24/
India's Biocon developing its own version of Wegovy, clinical trial likely next year
reuters.com/business/healthcare-pharmaceuticals/indias-biocon-developing-its-own-version-wegovy-clinical-trial-likely-next-year-2024-04-18/
Quick Glance: Biocon Developing Own Version of Wegovy, Plans Clinical Trial
- Indian pharmaceutical company Biocon is working on developing its own version of Novo Nordisk's popular Wegovy and is likely to conduct a clinical trial next year to enter the growing weight-loss drug market.
- Biocon's CEO, Siddharth Mittal, has expressed the company's intention to develop semaglutide, the active ingredient in Wegovy, for the Indian market, even if it requires a clinical trial.
- Biocon aims to introduce generic versions of weight-loss drugs in emerging markets such as Brazil, Mexico, and Saudi Arabia before the patent for semaglutide expires in those countries in 2026.
- The company is striving to obtain a waiver on clinical trials from Indian regulators and submit bioequivalence studies to demonstrate the effectiveness of their version of semaglutide. Biocon is making significant investments in generics research and development, including peptides for weight-loss drugs.
The weight loss drug Ozempic is not linked to suicidal thoughts, regulators say: The European Medicines Agency announced the findings of its nine-month review
qz.com/ema-ozempic-suicidal-thoughts-1851406145
It’s Not Just Weight Loss. Eli Lilly Obesity Drug Works on This Chronic Condition.
barrons.com/articles/eli-lilly-stock-obesity-sleep-1229e0a6
Paid articlePaid Cardinal Health Won’t Renew OptumRx Distribution Pact. Guidance Is Unchanged.: Cardinal Health’s pharmaceutical distribution contract with OptumRx will expire in ...
barrons.com/articles/cardinal-health-stock-optumrx-contract-dc7522e8
Paid articlePaid 23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid: 23andMe CEO Anne Wojcicki has voting control of about 49% over the DNA testing company.
barrons.com/articles/23andme-ceo-anne-wojcicki-buyout-048b5096
Paid articlePaid
Bullish signal for biotech shares: Will this solve one of Novo Nordisk's biggest problems?
boerse-online.de/nachrichten/aktien/bullisches-signal-fuer-biotech-aktie-loest-das-eines-der-groessten-probleme-von-novo-nordisk-20355342.html
Medicare beneficiaries could be eligible for Wegovy coverage, study shows
reuters.com/business/healthcare-pharmaceuticals/about-36-mln-medicare-beneficiaries-could-be-eligible-wegovy-coverage-study-2024-04-24/
DJT Stock Slips. Trump Is Set for $1.3 Billion Share Award.
barrons.com/articles/djt-stock-price-trump-media-truth-social-62871b98
Paid articlePaid DJT Stock Falls Again. Trump’s Stake Is Down by More Than $2 Billion.: Trump Media & Technology Group shares were dropping again early on Tuesday after a sharp ...
barrons.com/articles/djt-stock-price-sell-buy-trump-media-truth-social-f97b0e23
Paid articlePaid Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune: Vertex Pharmaceuticals announced a $4.9 billion deal to buy Alpine Immune ...
barrons.com/articles/vertex-pharmaceuticals-stock-alpine-immune-deal-a3a27f8e
Paid articlePaid Solventum Stock Is Cheap. Why Wall Street Says to Wait.: Solventum stock picked up two new ratings this week. Wall Street wants to see more growth from the 3M ...
barrons.com/articles/solventum-stock-price-3m-spinoff-4f6025e7
Paid articlePaid
Here’s Who Still Owns Trump Media Stock—and Could Be Getting Ready to Sell: Shares (ticker: DJT) of the Trump Media, the Truth Social owner, have plunged and may ...
barrons.com/articles/djt-stock-ownership-sales-31c6586b
Paid articlePaid DJT Stock Slips. Truth Social Co-Founders Are Challenging Trump Media Lockup.
barrons.com/articles/djt-stock-price-buy-sell-trump-media-truth-social-6acedadd
Paid articlePaid Who Is Buying DJT Stock? It’s a Mystery.: Public disclosures for Trump Media’s DJT, like all stocks, show very little about who’s ultimately behind the trading ...
barrons.com/articles/djt-truth-social-trump-media-stock-buying-a7bffe7d
Paid articlePaid Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.
barrons.com/articles/abbott-labs-earnings-stock-price-8645ed58
Paid articlePaid EU regulator to review reports of suicidal thoughts and weight loss drugs: A European Medicines Agency committee will this week hold a meeting related to its ...
reuters.com/business/healthcare-pharmaceuticals/eu-health-regulator-discuss-any-link-between-weight-loss-drugs-suicidal-thoughts-2024-04-08/
Novo Nordisk may buy German biotech company Cardior: The German biotech company Cardior is researching an active ingredient against heart failure and is now ...
diepresse.com/18385607/novo-nordisk-darf-deutsche-biotech-firma-cardior-kaufen
Novo Nordisk parent refiles US application on Catalent deal: The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S ...
reuters.com/markets/deals/novo-nordisk-parent-refiles-us-application-catalent-deal-2024-04-08/
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
cnbc.com/2024/04/20/weight-loss-drug-patients-spend-less-on-restaurants-takeout-survey.html
Popular weight loss drugs in tight supply as Zepbound shortage could last through June
abcnews.go.com/Health/popular-weight-loss-drugs-tight-supply-zepbound-shortage/story
Hundreds of websites have been hawking fake Ozempic and other weight loss drugs. More may be coming
qz.com/fake-ozempic-websites-shut-down-1851411488
Weight-loss drug startup Metsera wants to take on Novo and Lilly. Here’s what you need to know
fastcompany.com/91110090/metsera-startup-eli-lilly-novo-nordisk-competitor-weight-loss-drugs
Biocon leads India push into weight loss drugs as patents lapse: The Bengaluru-based firm is pivoting to anti-obesity therapies as patents for the blockbuster ...
dailymaverick.co.za/article/2024-04-08-biocon-leads-india-push-into-weight-loss-drugs-as-patents-lapse/
Eli Lilly vs. Novo Nordisk: Is this biotech stock ahead thanks to just one number?
boerse-online.de/nachrichten/aktien/eli-lilly-vs-novo-nordisk-hat-diese-biotech-aktie-dank-nur-einer-zahl-die-nase-vorn-20354696.html
Pfizer RSV Vaccine Could Get Wider Use. New Study Suggests a Benefit For All Adults.
barrons.com/articles/pfizer-fda-rsv-vaccine-shot-gsk-moderna-4b1d50cc
Paid articlePaid
Costco enters a controversial industry with its latest move: Costco is expanding one of its beloved programs to include coverage of a growing trend that has ...
thestreet.com/retail/costco-enters-a-controversial-industry-with-its-latest-move
Ozempic ‘oops’ babies spark debate about weight-loss shot use as fertility drugs: A surprising thing is happening to some women on weight-loss drugs who’ve ...
bostonherald.com/2024/04/22/ozempic-oops-babies-spark-debate-about-weight-loss-shot-use-as-fertility-drugs/
Medicines Agency: No Ozempic pregnancies in the EU: According to the European Medicines Agency, there are no cases of surprise pregnancies caused by Ozempic in ...
profil.at/wissenschaft/arzneimittelagentur-keine-ozempic-schwangerschaften-in-der-eu/402870968
Is the weight loss injection expensive hype or the big breakthrough?: We talk to doctor Harald Schneider and F.A.Z. editor Lucia Schmidt about the weight loss ...
faz.net/podcasts/f-a-z-podcast-fuer-deutschland/ist-die-abnehmspritze-teurer-hype-oder-der-grosser-durchbruch-19675445.html
Paid articlePaid
How one state is trying to make weight loss drugs cheaper: Weight loss drugs aren't covered by insurance for North Carolina's state employees ...
nbcnews.com/health/health-news/one-state-trying-make-weight-loss-drugs-cheaper-rcna148997
Run on new weight loss drugs: "Many don't even want their partner to know": Injections from Novo Nordisk and Eli Lilly promise quick slimming on prescription ...
spiegel.de/wirtschaft/unternehmen/wegovy-mounjaro-und-co-kommt-nach-der-abnehmspritze-bald-die-schlankheitspille-a-8d2b1f3f-ec7c-4888-86ae-5494aab96f0e
SHAREHOLDER hot stock Gubra: New arrow against pounds in the quiver: Another source of hope in the Danes' pipeline.
deraktionaer.de/artikel/pharma-biotech/aktionaer-hot-stock-gubra-neuer-pfeil-gegen-pfunde-im-koecher-20355945.html
Paid articlePaid
Equity funds: How SAP makes life difficult for fund managers: The rise of megacaps such as Microsoft, Novo Nordisk and SAP is increasingly becoming a problem for ...
capital.de/geld-versicherungen/aktienfonds--wie-sap-fondsmanagern-das-leben-schwer-macht-34650416.html
Paid articlePaid
Novo Nordisk Remains The Better Buy After A Moderate Pullback: Novo Nordisk (NVO) continues to be rated as a Buy, with the stock already charting an impressive ...
seekingalpha.com/article/4685043-novo-nordisk-better-buy-after-moderate-pullback
Paid articlePaid
Ozempic's latest reported side effect: pregnancy: A number of women are reporting unplanned pregnancies while taking drugs like Ozempic.
axios.com/2024/04/18/ozempic-pregnancy-weight-loss-drugs-fertility-report
Unlock your future with a Degree from Bar Ilan University
jpost.com/special-content/unlock-your-future-with-a-degree-from-bar-ilan-university-795932
Father of Korean life science research dies at 88 : He graduated from the College of Liberal Arts and Natural Sciences at Seoul National University in 1960 and ...
koreatimes.co.kr/www/nation/2024/04/119_373142.html
Ozempic Babies: Doctors Want Safety Data on Obesity Shots During Pregnancy: A surprising thing is happening to some women on weight-loss drugs who’ve struggled ...
bloomberg.com/news/articles/2024-04-18/ozempic-babies-doctors-want-safety-data-on-obesity-shots-during-pregnancy
Even more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
qz.com/eli-lilly-zepbound-shortage-fda-1851416991
Hanover: Federal Cartel Office approves Cardior takeover: The competition authority has no objections to the new owner Novo Nordisk. The Danes want to buy the ...
neuepresse.de/wirtschaft/regional/hannover-bundeskartellamt-genehmigt-cardior-uebernahme-XW42UM2WENCUFIMJY5IDDCXGEQ.html
Paid articlePaid One time chance? Eli Lilly and Novo Nordisk shares have even more potential than expected
boerse-online.de/nachrichten/aktien/einmalige-chance-die-aktien-von-eli-lilly-und-novo-nordisk-haben-noch-mehr-potenzial-als-gedacht-20355579.html
Federal Cartel Office approves purchase of Cardior: Hanover - The Danish pharmaceutical company Novo Nordisk is allowed to buy the biotech company Cardior ...
dlvr.it/T5kfLq
Eight stock picks in AI, obesity drugs and other growth areas beyond the S&P 500: Nicole Kornitzer of Buffalo Funds explains how she invests in ‘secular growth ...
marketwatch.com/story/eight-stock-picks-in-ai-obesity-drugs-e-commerce-and-other-growth-areas-beyond-the-s-p-500-1f84da89
U.S. Stocks Have Outperformed Europe for Years. Why That Could Change for a While.
barrons.com/articles/u-s-stocks-have-outperformed-europe-for-years-why-that-could-change-for-a-while-bf7f2ede
Paid articlePaid Costco enters a controversial industry with its latest move: Costco is expanding one of its beloved programs to include coverage of a growing trend that has ...
thestreet.com/retail/costco-enters-a-controversial-industry-with-its-latest-move
Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports: The company reported results of clinical trials involving Zepbound, an obesity drug in the ...
nytimes.com/2024/04/17/health/sleep-apnea-obesity-zepbound.html
Copenhagen's Børsen Tower Can Rise Again With Novo Nordisk's Help: Denmark should take lessons from the fire at Notre Dame — and how French luxury ...
bloomberg.com/opinion/articles/2024-04-16/copenhagen-s-ravaged-stock-exchange-can-rise-again-with-novo-nordisk-help
Paid articlePaid
Stigmatization affects the psychology of people with obesity: Every year, Novo Nordisk highlights a special topic from the complex clinical picture of obesity in ...
medical-tribune.de/medizin-und-forschung/artikel/die-unsichtbare-last-des-stigmas
Cardior bosses: “The market for our new drug is huge”: 65 million people worldwide suffer from heart failure. The Hanover company Cardior has developed a new ...
neuepresse.de/wirtschaft/regional/cardior-chefs-der-markt-fuer-unser-neues-medikament-ist-riesig-EQCAWCCSWJDGTOTSVFQV3CIGVA.html
Paid articlePaid Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They’re Safe.
barrons.com/articles/zoetis-stock-pet-arthritis-drugs-b3001b06
Paid articlePaid
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
fortune.com/europe/2024/04/10/astrazeneca-boss-pascal-soriot-pay/
Paid articlePaid Obesity-drug power duo Novo Nordisk and Eli Lilly have room to run, analysts say: BMO analysts cut price target for Amgen, another contender in the weight-loss ...
marketwatch.com/story/obesity-drug-power-couple-novo-nordisk-and-eli-lilly-still-have-room-to-run-analysts-say-c37743b9
Ozempic slimming injection: How pharmaceutical companies play patients off against each other
berliner-zeitung.de/open-source/abnehmspritze-ozempic-wie-pharmakonzerne-patienten-gegeneinander-ausspielen-li.2203936
Costco enters a controversial industry with its latest move: The retail giant is expanding one of its beloved programs to include a growing trend.
charlotteobserver.com/news/business/article287364065.html
Eli Lilly (LLY), Novo (NOVOB DC) Risk Missing High Expectations, Goldman Says: The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S ...
bloomberg.com/news/articles/2024-04-12/lilly-novo-euphoria-risks-disappointing-investors-goldman-says
Paid articlePaid AstraZeneca there: That's why these biotech stocks are now making hearts beat faster on Wall Street
boerse-online.de/nachrichten/aktien/astrazeneca-dabei-darum-lassen-diese-biotech-aktien-an-der-wall-street-jetzt-herzen-hoeher-schlagen--20354827.html
How the 'Oh-Oh-Oh Ozempic' Commercial Song Made a Musician $1 Million: David Paton's 1974 song "Magic" has been repurposed as the theme ...
entrepreneur.com/business-news/ozempic-song-used-in-commercial-makes-70s-rockers-millions/472492
3M Could Lose Its Elite Dividend Status After 64 Years. What It Means for the Stock.
barrons.com/articles/3m-lose-elite-dividend-status-23337728
Paid articlePaid Novo Nordisk: Deal with Ginkgo Bioworks is expanded - the details: The Danes are further expanding their partnership with the synthetic biology specialist.
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-deal-mit-ginkgo-bioworks-wird-erweitert-die-details-20354834.html
Wegovy’s heart benefits are not just linked with weight loss, new study suggests: Heart-failure patients with diabetes may shed fewer pounds on Wegovy but still ...
marketwatch.com/story/wegovys-heart-benefits-are-not-just-linked-with-weight-loss-new-study-suggests-1bfcf903
Meet Europe’s Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
barrons.com/articles/novo-nordisk-asml-lvmh-nestle-european-mag-stocks-554d95c7
Paid articlePaid Novo Nordisk: The Moat Won't Last Forever: Novo Nordisk is currently the preeminent player in this burgeoning GLP-1 market space. Click here to read an analysis ...
seekingalpha.com/article/4682909-novo-nordisk-the-moat-wont-last-forever
Paid articlePaid These Stocks Are Moving the Most Today: Trump Media, Tesla, Maxeon, Tilray, and More
barrons.com/articles/stock-market-movers-c65f7589
Paid articlePaid Eli Lilly's weight loss injection: explosive device for the German health system: Eli Lilly, the largest pharmaceutical company in the world, will soon be ...
capital.de/wirtschaft-politik/eli-lillys-abnehmspritze--sprengsatz-fuers-deutsche-gesundheitssystem-34607690.html
I Invested in Ozempic—It Taught Me a Valuable Lesson: It is now more valuable than Tesla.
newsweek.com/i-invested-ozempic-it-taught-me-valuable-lesson-1887867
DJT Stock Slips. Trump Is Suing Co-Founders of the Truth Social Parent.: Trump Media & Technology Group was falling early on Wednesday. Its majority owner Donald ...
barrons.com/articles/djt-stock-price-trump-truth-social-buy-sell-d2249f43
Paid articlePaidQuick Glance: Donald Trump's Media Company Faces Financial Challenges in 2023
- Following a high-profile stock market debut, Donald Trump's social media company reported significant losses, with nearly $58.2 million lost last year, resulting in a stock price decline of over 21%.
- Revenue for Trump Media in 2023 totaled $4.1 million, showing an increase from $1.5 million in 2022.
- Trump Media began trading on the Nasdaq under the symbol DJT on March 26, experiencing volatility as the stock closed at $48.66 after Monday's sell-off.
- Analysts have drawn comparisons between the excitement surrounding Trump Media and the meme stock frenzy that boosted shares of companies like GameStop and AMC Entertainment in 2021.
Weed Stocks Are in the Green Again: Weed now seems back in vogue. From last summer’s low, the Pure US Cannabis ETF has doubled, to a recent $10.25.
barrons.com/articles/aurora-trulieve-curaleaf-canopy-cannabis-weed-stocks-20d424f2
Paid articlePaid Costco is now prescribing Ozempic, Wegovy, and other weight loss drugs: The warehouse club is offering prescriptions for weight loss drugs through its health ...
qz.com/costco-ozempic-wegovy-weight-loss-drugs-prescription-1851382263
Paid articlePaid Today, General Electric Will Be No More—Sort of.: The venerable conglomerate is being broken into three pieces.
barrons.com/articles/general-electric-breakup-1babaaa5
Paid articlePaid Eli Lilly’s Ozempic Competitors Face Risks. Why the Stock Has More Upside.
barrons.com/articles/eli-lilly-ozempic-stock-upside-22292ed5
Paid articlePaid ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
barrons.com/articles/ars-pharmaceuticals-nuvalent-and-more-stocks-see-action-from-activist-investors-055469cc
Paid articlePaid Drugmaker seeks approval for China's first biosimilar Ozempic: A drugmaker in China has developed a biosimilar version of Novo Nordisk's popular diabetes drug ...
reuters.com/business/healthcare-pharmaceuticals/chinas-first-biosimilar-ozempic-drug-applies-approval-2024-04-03/
TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript: TriSalus Life Sciences, Inc. (NASDAQ:NASDAQ:TLSI) Q4 2023 Earnings Conference Call April 1 ...
seekingalpha.com/article/4681511-trisalus-life-sciences-inc-tlsi-q4-2023-earnings-call-transcript
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk: Novo Nordisk is Friday's IBD Stock Of The Day. After hitting a record high in March ...
investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-pullback-weight-loss-drugs/
Next
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics